The dopamine receptor antagonist haloperidol disrupts behavioral responses of sea urchins and sea stars. 2023

Emma Howell, and Abigail Lancaster, and Jordan Besh, and Bea Richardson, and Eileen Gomez, and Sophia Harnew-Spradley, and Chris Shelley
Biology Department, The University of the South, Sewanee, TN 37383, USA.

Despite lacking a brain and having an apparent symmetrically pentaradial nervous system, echinoderms are capable of complex, coordinated directional behavioral responses to different sensory stimuli. However, very little is known about the molecular and cellular mechanisms underlying these behaviors. In many animals, dopaminergic systems play key roles in motivating and coordinating behavior, and although the dopamine receptor antagonist haloperidol has been shown to inhibit the righting response of the sea urchin Strongylocentrotus purpuratus, it is not known whether this is specific to this behavior, in this species, or whether dopaminergic systems are needed in general for echinoderm behaviors. We found that haloperidol inhibited multiple different behavioral responses in three different echinoderm species. Haloperidol inhibited the righting response of the sea urchin Lytechinus variegatus and of the sea star Luidia clathrata. It additionally inhibited the lantern reflex of S. purpuratus, the shell covering response of L. variegatus and the immersion response of L. variegatus, but not S. purpuratus or L. clathrata. Our results suggest that dopamine is needed for the neural processing and coordination of multiple different behavioral responses in a variety of different echinoderm species.

UI MeSH Term Description Entries
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012617 Sea Urchins Somewhat flattened, globular echinoderms, having thin, brittle shells of calcareous plates. They are useful models for studying FERTILIZATION and EMBRYO DEVELOPMENT. Echinoidea,Sand-Dollar,Clypeasteroida,Sand Dollars,Clypeasteroidas,Dollar, Sand,Dollars, Sand,Echinoideas,Sand Dollar,Sand-Dollars,Sea Urchin,Urchin, Sea,Urchins, Sea
D013215 Starfish Echinoderms having bodies of usually five radially disposed arms coalescing at the center. Sea Star,Seastar,Starfishes,Sea Stars,Seastars
D018492 Dopamine Antagonists Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. Dopamine Antagonist,Dopamine Blocker,Dopamine Receptor Antagonist,Dopamine Receptor Antagonists,Dopaminergic Antagonist,Dopaminergic Antagonists,Antagonists, Dopamine,Antagonists, Dopamine Receptor,Antagonists, Dopaminergic,Dopamine Blockers,Antagonist, Dopamine,Antagonist, Dopamine Receptor,Antagonist, Dopaminergic,Blocker, Dopamine,Blockers, Dopamine,Receptor Antagonist, Dopamine,Receptor Antagonists, Dopamine

Related Publications

Emma Howell, and Abigail Lancaster, and Jordan Besh, and Bea Richardson, and Eileen Gomez, and Sophia Harnew-Spradley, and Chris Shelley
January 2000, Methods in molecular biology (Clifton, N.J.),
Emma Howell, and Abigail Lancaster, and Jordan Besh, and Bea Richardson, and Eileen Gomez, and Sophia Harnew-Spradley, and Chris Shelley
June 1973, The Journal of cell biology,
Emma Howell, and Abigail Lancaster, and Jordan Besh, and Bea Richardson, and Eileen Gomez, and Sophia Harnew-Spradley, and Chris Shelley
June 2005, The Journal of experimental biology,
Emma Howell, and Abigail Lancaster, and Jordan Besh, and Bea Richardson, and Eileen Gomez, and Sophia Harnew-Spradley, and Chris Shelley
January 1990, Neuropsychobiology,
Emma Howell, and Abigail Lancaster, and Jordan Besh, and Bea Richardson, and Eileen Gomez, and Sophia Harnew-Spradley, and Chris Shelley
September 1975, Life sciences,
Emma Howell, and Abigail Lancaster, and Jordan Besh, and Bea Richardson, and Eileen Gomez, and Sophia Harnew-Spradley, and Chris Shelley
August 2014, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
Emma Howell, and Abigail Lancaster, and Jordan Besh, and Bea Richardson, and Eileen Gomez, and Sophia Harnew-Spradley, and Chris Shelley
January 2024, BMC microbiology,
Emma Howell, and Abigail Lancaster, and Jordan Besh, and Bea Richardson, and Eileen Gomez, and Sophia Harnew-Spradley, and Chris Shelley
January 2018, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
Emma Howell, and Abigail Lancaster, and Jordan Besh, and Bea Richardson, and Eileen Gomez, and Sophia Harnew-Spradley, and Chris Shelley
January 2008, ChemMedChem,
Emma Howell, and Abigail Lancaster, and Jordan Besh, and Bea Richardson, and Eileen Gomez, and Sophia Harnew-Spradley, and Chris Shelley
April 2014, Behavioural brain research,
Copied contents to your clipboard!